Front Yard Residential Corporation (NYSE:RESI)
Front Yard Residential Corporation, operates as a Real Estate Investment Trust (REIT). It acquires single-family rental properties primarily through the acquisition of sub-performing and non-performing loan portfolios. Front Yard Residential formerly known as Altisource Residential Corporation, is based in Christiansted, Virgin Islands.
Front Yard Residential Corporation (NYSE:RESI)’s Financial Overview
Front Yard Residential Corporation (NYSE) declined -6.01% yesterday to close its trading session at $9.23. The company has 1 year Price Target of $13. Front Yard Residential Corporation has 52-Week high of $13.07 and 52-Week Low of $7.99. The stock touched its 52-Week High on 13.07 and 52-Week Low on 7.99. The stock traded with the volume of 1.27 Million shares yesterday. The firm shows the market capitalization of $500.54 Million.
Front Yard Residential Corporation (NYSE) reported its last quarterly earnings on 9/29/2018 where the firm reported its Actual EPS of $-0.89/share against the analyst consensus estimate of $-0.39/share. The difference between the actual and expected EPS is $-0.5 a share with a surprise factor of -128.2%.
The firm is trading with SMA20 of 0.02 Percent, SMA50 of 2 Percent and SMA200 of -10.04 percent. Front Yard Residential Corporation has P/S value of 3.21 while its P/B value stands at 0.94. Similarly, the company has Return on Assets of -6.6 percent, Return on Equity of -22.7 percent and Return on Investment of -9.7 Percent. The company shows Gross Margin and Operating Margin of 56.9 percent and -86.6 percent respectively.
The Stock currently has Analyst’ mean Recommendation of 0 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.
The 6 analysts offering 12-month price forecasts for Front Yard Residential Corp have a median target of 13.00, with a high estimate of 15.00 and a low estimate of 10.00. The median estimate represents a +40.85% increase from the last price of 9.23.
Front Yard Residential Corporation is estimated to report earnings on 03/07/2019. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates.Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts’ forecasts, the consensus EPS forecast for the quarter is $0.02.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)
Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies. Alexion is the global leader in complement inhibition and has developed and commercializes the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) & atypical hemolytic uremic syndrome (aHUS) & and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG). In addition, Alexion has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D).
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)’s Financial Outlook
The 19 analysts offering 12-month price forecasts for Alexion Pharmaceuticals Inc have a median target of 165.00, with a high estimate of 190.00 and a low estimate of 125.00. The median estimate represents a +53.37% increase from the last price of 107.58.
Alexion Pharmaceuticals, Inc. is expected* to report earnings on 02/04/2019 before market open. The report will be for the fiscal Quarter ending Dec 2018. According to Zacks Investment Research, based on 7 analysts’ forecasts, the consensus EPS forecast for the quarter is $1.61. The reported EPS for the same quarter last year was $1.28.
According to Zacks Investment Research, Alexion Pharmaceuticals, Inc. has a Consensus Recommendation of 1.35. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).
The Stock declined -3.19% and closed its last trading session at $107.58. The company has the market capitalization of $23.96 Billion. The stock has 52-week high of $140.77 and 52-Week low of $92.56. The firm touched its 52-Week high on 140.77 and 52-Week low on 92.56. The company has volume of 1.64 Million shares. The company has a total of 222.7 Million shares outstanding.
Alexion Pharmaceuticals, Inc. (NASDAQ) in the last quarter reported its actual EPS of $2.02/share where the analyst estimated EPS was $1.74/share. The difference between the actual and Estimated EPS is $0.28. This shows a surprise factor of 16.1 percent.
The company has YTD performance of 10.5 percent. Beta for Alexion Pharmaceuticals, Inc. stands at 1.44 while its ATR (average true range) is 4.52. The company has Weekly Volatility of 3.05%% and Monthly Volatility of 4.44%%.
Alexion Pharmaceuticals, Inc. has distance from 20-day Simple Moving Average (SMA20) of 3.78%, Distance from 50-Day Simple Moving Average of -5.07 percent and Distance from 200-Day Simple Moving Average of -9.99%.
The Company currently has ROA (Return on Assets) of 1.1 percent, Return on Equity (ROE) of 1.7 Percent and Return on Investment (ROI) of 4.7% with Gross margin of 89.2 percent and Operating & Profit margin of 8.6% and 3.9% respectively.